Genomics of renal cell cancer - Does it provide breakthrough?

Pathology and Oncology Research

Volumn 12, Issue 1, 2006, Pages 5-11

  Kopper, László ^a   Tímár, József ^b  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Genomics; Prognostic markers; Renal cell cancer; Targeted therapy

Indexed keywords

CARBONATE DEHYDRATASE IX; CD74 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GALECTIN 3; GAMMA INTERFERON; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 2; PARVALBUMIN; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VIMENTIN;

BIRT HOGG DUBE SYNDROME; CARCINOGENESIS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA REPLICATION; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; GENE CONTROL; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MICROARRAY ANALYSIS; PH; PROTEIN DEGRADATION; REVIEW; TUMOR SUPPRESSOR GENE; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; VON HIPPEL LINDAU DISEASE;

CARCINOMA, RENAL CELL; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; KIDNEY NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 33645972282     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893425     Document Type: Review

References (57)

1. Beniers AJ, Peelen WP, Debruyne FM, Schalken JA: HLA-class-I and -class-II expression on renal tumor xenografts and the relation to sensitivity for alpha-IFN, gamma-IFN and TNF. Int J Cancer 48: 709-716, 1991
2. Boer JM, Huber WK, Sültmann H, et al: Identification and classification on differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res 11:1861-1870, 2001
3. Bromwich E, McMillan DC, Lamb GW, et al: The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br J Cancer 91:1236-1238, 2004
4. Bromwich EJ, McArdle PA, Canna K, et al: The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer. Br J Cancer 89:1906-1908, 2003
5. Bui MH, Seligson D, Han KR, et al: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9: 802-811, 2003
6. Bui MH, Visapaa H, Seligson D, et al: Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 171:2461-2466, 2004
7. Campbell L, Gumbleton M, Griffiths DF: Caveolin-1 overexpression predicts poor disease-free survival of patients with clinically confined renal cell carcinoma. Br J Cancer 89:1909-1913, 2003
8. Castillo M, Petit A, Mellado B, et al: C-kit expression in sarcomatoid renal cell carcinoma: potential therapy with imatinib. J Urol 171:2176-2180, 2004
9. Chautard D, Dalifard I, Chassevent A, et al: Prognostic value of uPA, PAI-1, and DNA content in adult renal cell carcinoma. Urol 63:1055-1060, 2004
10. Dancey JE: Epidermal growth factor receptor and epidermal growth factor receptor therapies in renal cell carcinoma: do we need a better mouse trap? J Clin Oncol 22: 2975-2977, 2004
11. Dawson NA, Guo C, Zak R, et al: A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma. Clin Cancer Res 10: 7812-7819, 2004
12. Donskov F, Bennedsgarrd KM, Hokland M, et al: Leukocyte orchestration in blood and tumour tissue following interlukin-2 based immunotherapy in metastatic renal cell carcinoma. Cancer Immunol Immunother 53: 729-739, 2004
13. Foon KA, Yand XD, Wiener LM, et al: Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 58: 984-990, 2004
14. Gollob JA: Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. Clin Genitourin Cancer 4: 167-174, 2005
15. Jacobsen J, Grankvist K, Rasmuson T, et al: Expression of vascular endothelial growth factor protein in human renal cell carcinoma. BJU Int 93:297-302, 2004
16. Jermann M, Stahel RA, Salzberg M, et al: A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 57: 533-539, 2006
17. Joo HJ, Oh DK, Kim YS, et al: Increased expression of caveolin-1 and microvessel density correlates with metastasis and poor prognosis in clear cell renal cell carcinoma. BJU Int 93:291-296, 2004
18. Kawata N, Yagasaki H, Hirakata H, et al: The impact of angiogenesis on the prognosis of advanced renal cell carcinoma. Hinyokika Kiyo 50:157-163, 2004
19. Kim HL, Seligson D, Liu X, et al: Using protein expression to predict survival in clear cell renal carcinoma. Clin Canc Res 10: 5464-5471, 2004
20. Kovacs G: Molecular differential pathology of renal tumors. Histopathology 22: 1-8, 1993
21. Kovacs G, Akhtar M, Beckwith BJ, et al: The Heidelberg classification of renal cell tumors. J Pathol 183: 131-133, 1997
22. Lam JS, Belldegrun AS, Figlin RA: Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin Cancer Res 10: 6304s-6309s, 2004
23. Langner C, Ratschek M, Rehak P, et al: Steroid hormone receptor expression in renal cell carcinoma: an immunohistochemical analysis of 182 tumors. J Urol 171:611-614, 2004.
24. Langner C, Ratschek M, Rehak P, et al: Are heterogenous results of EGFR immunoreactivity in renal carcinoma related to non-standardised criteria for staining evaluation? J Clin Pathol 57:773-775, 2004
25. Lee S-W, Lee K-I, Kim JY: Revealing urologic diseases by proteomic technique. J Chromatogr B Analyt Technol Biomed Life Sci 815: 203-213, 2005
26. Linehan WM, Vasselli J, Srinivasan R, et al: Genetic basis of cancer of the kidney: disease-specific approaches to therapy. Clin Cancer Res 10, 6282s-6289s, 2004
27. Liou LS, Shi T, Duan Z-H, et al: Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol 4:1-11, 2004
28. Lorincz T, Tímár J, Szendroi M: Alterations of microvascular density in bone metastases of adenocarcinoma. Pathol Oncol Res 10: 149-153, 2004
29. Mekhail TM, Kawanishi-Tabata R, Tubbs R, et al: Renal cell carcinoma (RCC) and telomerase activity: relationship to stage. Urol Oncol 21:424-430, 2003
30. Moch H, Sauter G, Buchholz N, et al: Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma. Hum Pathol 28: 1255-1259, 1997
31. Moch H: Genomic alterations in renal tumours: what have we learned in the era of comparative genomic hybridisation? Pathology 36: 51-57, 2004
32. Motzer RJ, Michaelson D, Redman BG, et al: Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24: 16-24, 2006
33. Negrier S, Perol D, Menetier-Caux C, et al: Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6 - from the Groupe Francais d'Immunothérapie. J Clin Oncol 22:2371-2378, 2004
34. Padrik P: Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Med Oncol 20:325-334, 2003
35. Pantuck AJ, Zeng G, Belldegrun AS, Figlin RA: Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res 9:4641-4652, 2003
36. Paul R, Necknig U, Busch R, et al: Cadherin-6: a new prognostic marker for renal cell carcinoma. J Urol 171:97-101, 2004
37. Pavlovich CP, Schmidt LS: Searching for the hereditary causes of renal cell carcinoma. Nat Rev Cancer 4: 381-393, 2004
38. Ramp U, Krieg T, Caliskan E, et al: XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol 35:1022-1088, 2004
39. Richard S, Lidereau R, Giraud S: The growing family of hereditary renal cell carcinoma. Nephrol Dial Transplant 19: 2954-2958, 2004
40. Rini BI, Small EJ: Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23: 1028-1043, 2005
41. Rioux-Leclercq N, Delcros JG, Bansard JY, et al: Immunohistochemical analysis of tumor polyamines discriminates high-risk patients undergoing nephrectomy for renal cell carcinoma. Hum Pathol 35:1279-1284, 2004
42. Roemer A, Schwetmann L, Jung M, et al: Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. Oncol Rep 11:529-536, 2004
43. Royston P, Sauerbrei W, Ritchie A: Is treatment with interferon-α effective in all patients with metastatic renal carcinoma? A new approach to the investigation of interactions. Br J Cancer 90:794-799, 2004
44. Sakaeda T, Okumura N, Gotoh A, et al: EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharm Res 22: 1757-1761, 2005
45. Shimazui T, Yoshikawa K, Uemura H, et al: The level of cadherin-6 mRNA in peripheral blood is associated with the site of metastasis and with the subsequent occurrence of metastases in renal cell carcinoma. Cancer 101:963-968, 2004
46. Staehler M, Rohrmann K, Haseke N, et al: Target agents for the treatment of advanced renal cell carcinoma. Curr Drug Targets 6: 835-846, 2005
47. Staller P, Sulitkova J, Lisztwan J, et al: Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumor suppressor pVHL. Nature 425: 307-311, 2003
48. Sufan RI, Jewett MAS, Ohh M: The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am J Physiol Renal Physiol 287: F1-F6, 2004
49. Takahashi M, Rhodes DR, Furge KA, et al: Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 98: 9754-9759, 2001
50. Tan M-H, Rogers CG, Cooper JT, et al: Gene expression profiling of renal cell carcinoma. Clin Cancer Res 10: 6315s-6321s, 2004
51. Twine NC, Stover JA, Marshall B, et al: Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res 63: 6069-6075, 2003
52. Uhlman DL, Nguyen P, Manivel JC, et al: Epidermal growth factor receptor and transforming growth factor alpha expression in papillary and nonpapillary renal cell carcinoma: correlation with metastatic behavior and prognosis. Clin Cancer Res 1: 913-920, 1995
53. Vasselli JR, Shih JH, Iyengar SR, et al: Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 100: 6958-6963, 2003
54. Vogelzang NJ: Treatment options in metastatic renal carcinoma: an embarrassment of riches. J Clin Oncol 24: 1-3, 2006
55. Wittnehel S, Jalil A, Thiery J, et al: The sensitivity of renal cell carcinoma cells to interferon alpha correlates with p53-induction and involves Bax. Eur Cytokine Netw 16: 123-127, 2005
56. Yildiz E, Gokce G, Kilicarslan H, et al: Prognostic value of the expression of Ki-67, CD44 and vascular endothelial growth factor, and microvessel invasion, in renal cell carcinoma. BJU Int 93:1087-1093, 2004
57. Zigeuner R, Ratschek M, Rehak P, et al: Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651-655, 2004